128 filings
Page 3 of 7
6-K
4qbv8bu1y6p1k 0k744m
22 Nov 21
Obseva Announces U.S. FDA Acceptance of New Drug Application for Linzagolix
6:05am
6-K
m1cyl4
4 Nov 21
Index to Unaudited Condensed Consolidated Financial Statements
7:21am
6-K
5vb2g01
29 Oct 21
ObsEva Announces Management Change
5:24pm
6-K/A
1332ae61
13 Oct 21
ObsEva Announces Relationship with Syneos Health to Commercialize Linzagolix
5:24pm
6-K
mzon56e9 rx
13 Oct 21
ObsEva Announces Relationship with Syneos Health to Commercialize Linzagolix
9:27am
6-K
c9pkzo
5 Aug 21
Index to Unaudited Condensed Consolidated Financial Statements
6:04am
6-K
d8ahy h8mf
27 Jul 21
Current report (foreign)
6:12am
6-K
5v34izp8c6ix
1 Jun 21
ObsEva SA Announces that Shareholders Approved all Board Proposals at its
6:30am
6-K
e7a3q3
25 May 21
ObsEva Announces Proposed Changes to the Composition of its
5:22pm
6-K
ko5ed86f462qw npn
20 May 21
ObsEva Announces Final Results from the Phase 3 PRIMROSE Program of
6:30am
6-K
51sp8is3j
6 May 21
ObsEva appoints Clive Bertram as Chief Commercial Officer
6:05am
6-K
4zbqbw5
6 May 21
Index to Unaudited Condensed Consolidated Financial Statements
6:03am
6-K
3u92r
22 Apr 21
ObsEva Annual General Meeting 2021
6:31am
6-K
zpa yl5z2zh1
31 Mar 21
Current report (foreign)
7:15am
6-K
g6c2x
5 Mar 21
Current report (foreign)
8:15am
6-K
w9rha4adl6
5 Mar 21
ObsEva Announces Year End 2020 Financial Results
7:21am
6-K
izuw24r51ww4
17 Feb 21
ObsEva to Present at the SVB Leerink 10th Annual Global Healthcare Conference
6:04am
6-K
ona6 un0e1tyd524v7
11 Feb 21
ObsEva to Increase Issued Share Capital by Creating Additional Treasury Shares
6:08am
6-K
339qtdka3l22y3thklj
10 Feb 21
ObsEva Provides Business Outlook for 2021
6:10am
6-K
ruc2ni0
28 Jan 21
ObsEva to Increase Issued Share Capital by Creating
4:26pm